Jefferson Launches Clinical Trial Of Transmyocardial Laser Revascularization
Thomas Jefferson University Hospital is participating in a multicenter,
FDA approved, randomized, phase II clinical trial of transmyocardial laser
revascularization (TMLR), a new procedure that offers hope for patients
with refractory angina who are not candidates for traditional revascularization
TMLR is accomplished using a Holmium-YAG laser to create full thickness
1-mm channels in regions of ischemic myocardium. This is performed via an
incision into the chest wall without cardiopulmonary bypass. The channels
promote blood flow from the ventricular cavity, which stimulates the development
of blood vessels.
"Patients who have undergone TMLR experience dramatic relief of anginal
symptoms, improved exercise tolerance and decreased hospital admissions
for angina," explains Thomas Carter, MD, principal investigator and
Assistant Professor in the Division of Cardiothoracic Surgery.
Ideal candidates for TMLR are patients with Canadian Class III or IV angina
on maximum medical therapy who are not candidates for CABG or PTCA.